Lenskart Solutions Limited (BSE: LENSKART.BO) Stock Competitors & Peer Comparison
See LENSKART.BO's competitors and their performance on the BSE and across the wider stock market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for LENSKART.BO and its BSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LENSKART.BO | ₹706.60 | +3.94% | 1.2T | 243.62 | ₹2.90 | N/A |
| LENSKART.NS | ₹707.20 | +4.01% | 1.2T | 243.83 | ₹2.90 | N/A |
| MOLBIO.NS | ₹1,288.30 | +0.23% | 161.4B | 111.26 | ₹11.58 | N/A |
| MOLBIO.BO | ₹1,288.60 | +0.28% | 148.5B | 111.29 | ₹11.58 | N/A |
| VOEPL.BO | ₹507.35 | +3.40% | 16.2B | 101.67 | ₹4.99 | N/A |
| HSIL.BO | ₹415.00 | -2.24% | 5.9B | 27.78 | ₹14.94 | N/A |
| YASHOPTICS.NS | ₹133.90 | +1.44% | 3.3B | 41.07 | ₹3.26 | N/A |
| RAAJMEDI.BO | ₹102.49 | -0.24% | 1.4B | 119.17 | ₹0.86 | N/A |
| CHOKSI.BO | ₹228.70 | -0.54% | 1.3B | -326.71 | -₹0.70 | N/A |
| SHREEPAC.BO | ₹159.40 | +7.52% | 597.7M | 144.91 | ₹1.10 | N/A |
Stock Comparison
Lenskart Solutions Limited (NSE: LENSKART.NS)
LENSKART.BO vs LENSKART.NS Comparison September 2026
Lenskart Solutions Limited (BSE: LENSKART.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LENSKART.BO stands at 1.2T. In comparison, LENSKART.NS has a market cap of 1.2T. Regarding current trading prices, LENSKART.BO is priced at ₹706.60 on the BSE, while LENSKART.NS trades at ₹707.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LENSKART.BO currently has a P/E ratio of 243.62, whereas LENSKART.NS's P/E ratio is 243.83. In terms of profitability, LENSKART.BO's ROE is +0.09%, compared to LENSKART.NS's ROE of N/A. Regarding short-term risk, LENSKART.BO is similarly volatile compared to LENSKART.NS. This indicates similar risk in terms of short-term price fluctuations for LENSKART.BO.Check LENSKART.NS's competition here
Molbio Diagnostics Limited (NSE: MOLBIO.NS)
LENSKART.BO vs MOLBIO.NS Comparison September 2026
Lenskart Solutions Limited (BSE: LENSKART.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LENSKART.BO stands at 1.2T. In comparison, MOLBIO.NS has a market cap of 161.4B. Regarding current trading prices, LENSKART.BO is priced at ₹706.60 on the BSE, while MOLBIO.NS trades at ₹1,288.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LENSKART.BO currently has a P/E ratio of 243.62, whereas MOLBIO.NS's P/E ratio is 111.26. In terms of profitability, LENSKART.BO's ROE is +0.09%, compared to MOLBIO.NS's ROE of N/A. Regarding short-term risk, LENSKART.BO is more volatile compared to MOLBIO.NS. This indicates higher risk in terms of short-term price fluctuations for LENSKART.BO.Check MOLBIO.NS's competition here
Molbio Diagnostics Limited (BSE: MOLBIO.BO)
LENSKART.BO vs MOLBIO.BO Comparison September 2026
Lenskart Solutions Limited (BSE: LENSKART.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LENSKART.BO stands at 1.2T. In comparison, MOLBIO.BO has a market cap of 148.5B. Regarding current trading prices, LENSKART.BO is priced at ₹706.60 on the BSE, while MOLBIO.BO trades at ₹1,288.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LENSKART.BO currently has a P/E ratio of 243.62, whereas MOLBIO.BO's P/E ratio is 111.29. In terms of profitability, LENSKART.BO's ROE is +0.09%, compared to MOLBIO.BO's ROE of N/A. Regarding short-term risk, LENSKART.BO is more volatile compared to MOLBIO.BO. This indicates higher risk in terms of short-term price fluctuations for LENSKART.BO.Check MOLBIO.BO's competition here
Virtuoso Optoelectronics Limit (BSE: VOEPL.BO)
LENSKART.BO vs VOEPL.BO Comparison September 2026
Lenskart Solutions Limited (BSE: LENSKART.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LENSKART.BO stands at 1.2T. In comparison, VOEPL.BO has a market cap of 16.2B. Regarding current trading prices, LENSKART.BO is priced at ₹706.60 on the BSE, while VOEPL.BO trades at ₹507.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LENSKART.BO currently has a P/E ratio of 243.62, whereas VOEPL.BO's P/E ratio is 101.67. In terms of profitability, LENSKART.BO's ROE is +0.09%, compared to VOEPL.BO's ROE of +0.05%. Regarding short-term risk, LENSKART.BO is more volatile compared to VOEPL.BO. This indicates higher risk in terms of short-term price fluctuations for LENSKART.BO.Check VOEPL.BO's competition here
Hemant Surgical Industries Ltd. (BSE: HSIL.BO)
LENSKART.BO vs HSIL.BO Comparison September 2026
Lenskart Solutions Limited (BSE: LENSKART.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LENSKART.BO stands at 1.2T. In comparison, HSIL.BO has a market cap of 5.9B. Regarding current trading prices, LENSKART.BO is priced at ₹706.60 on the BSE, while HSIL.BO trades at ₹415.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LENSKART.BO currently has a P/E ratio of 243.62, whereas HSIL.BO's P/E ratio is 27.78. In terms of profitability, LENSKART.BO's ROE is +0.09%, compared to HSIL.BO's ROE of +0.14%. Regarding short-term risk, LENSKART.BO is more volatile compared to HSIL.BO. This indicates higher risk in terms of short-term price fluctuations for LENSKART.BO.Check HSIL.BO's competition here
Yash Optics & Lens Ltd. (NSE: YASHOPTICS.NS)
LENSKART.BO vs YASHOPTICS.NS Comparison September 2026
Lenskart Solutions Limited (BSE: LENSKART.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LENSKART.BO stands at 1.2T. In comparison, YASHOPTICS.NS has a market cap of 3.3B. Regarding current trading prices, LENSKART.BO is priced at ₹706.60 on the BSE, while YASHOPTICS.NS trades at ₹133.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LENSKART.BO currently has a P/E ratio of 243.62, whereas YASHOPTICS.NS's P/E ratio is 41.07. In terms of profitability, LENSKART.BO's ROE is +0.09%, compared to YASHOPTICS.NS's ROE of N/A. Regarding short-term risk, LENSKART.BO is more volatile compared to YASHOPTICS.NS. This indicates higher risk in terms of short-term price fluctuations for LENSKART.BO.Check YASHOPTICS.NS's competition here
Raaj Medisafe India Limited (BSE: RAAJMEDI.BO)
LENSKART.BO vs RAAJMEDI.BO Comparison September 2026
Lenskart Solutions Limited (BSE: LENSKART.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LENSKART.BO stands at 1.2T. In comparison, RAAJMEDI.BO has a market cap of 1.4B. Regarding current trading prices, LENSKART.BO is priced at ₹706.60 on the BSE, while RAAJMEDI.BO trades at ₹102.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LENSKART.BO currently has a P/E ratio of 243.62, whereas RAAJMEDI.BO's P/E ratio is 119.17. In terms of profitability, LENSKART.BO's ROE is +0.09%, compared to RAAJMEDI.BO's ROE of +0.06%. Regarding short-term risk, LENSKART.BO is more volatile compared to RAAJMEDI.BO. This indicates higher risk in terms of short-term price fluctuations for LENSKART.BO.Check RAAJMEDI.BO's competition here
Choksi Asia Limited (BSE: CHOKSI.BO)
LENSKART.BO vs CHOKSI.BO Comparison September 2026
Lenskart Solutions Limited (BSE: LENSKART.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LENSKART.BO stands at 1.2T. In comparison, CHOKSI.BO has a market cap of 1.3B. Regarding current trading prices, LENSKART.BO is priced at ₹706.60 on the BSE, while CHOKSI.BO trades at ₹228.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LENSKART.BO currently has a P/E ratio of 243.62, whereas CHOKSI.BO's P/E ratio is -326.71. In terms of profitability, LENSKART.BO's ROE is +0.09%, compared to CHOKSI.BO's ROE of +0.13%. Regarding short-term risk, LENSKART.BO is more volatile compared to CHOKSI.BO. This indicates higher risk in terms of short-term price fluctuations for LENSKART.BO.Check CHOKSI.BO's competition here
Shree Pacetronix Limited (BSE: SHREEPAC.BO)
LENSKART.BO vs SHREEPAC.BO Comparison September 2026
Lenskart Solutions Limited (BSE: LENSKART.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LENSKART.BO stands at 1.2T. In comparison, SHREEPAC.BO has a market cap of 597.7M. Regarding current trading prices, LENSKART.BO is priced at ₹706.60 on the BSE, while SHREEPAC.BO trades at ₹159.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LENSKART.BO currently has a P/E ratio of 243.62, whereas SHREEPAC.BO's P/E ratio is 144.91. In terms of profitability, LENSKART.BO's ROE is +0.09%, compared to SHREEPAC.BO's ROE of +0.19%. Regarding short-term risk, LENSKART.BO is less volatile compared to SHREEPAC.BO. This indicates lower risk in terms of short-term price fluctuations for LENSKART.BO.Check SHREEPAC.BO's competition here
Mohini Health & Hygiene Ltd. (NSE: MHHL.NS)
LENSKART.BO vs MHHL.NS Comparison September 2026
Lenskart Solutions Limited (BSE: LENSKART.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LENSKART.BO stands at 1.2T. In comparison, MHHL.NS has a market cap of 558M. Regarding current trading prices, LENSKART.BO is priced at ₹706.60 on the BSE, while MHHL.NS trades at ₹30.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LENSKART.BO currently has a P/E ratio of 243.62, whereas MHHL.NS's P/E ratio is 9.53. In terms of profitability, LENSKART.BO's ROE is +0.09%, compared to MHHL.NS's ROE of N/A. Regarding short-term risk, LENSKART.BO is more volatile compared to MHHL.NS. This indicates higher risk in terms of short-term price fluctuations for LENSKART.BO.Check MHHL.NS's competition here
KMS Medisurgi Limited (BSE: KMSMEDI.BO)
LENSKART.BO vs KMSMEDI.BO Comparison September 2026
Lenskart Solutions Limited (BSE: LENSKART.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LENSKART.BO stands at 1.2T. In comparison, KMSMEDI.BO has a market cap of 438.2M. Regarding current trading prices, LENSKART.BO is priced at ₹706.60 on the BSE, while KMSMEDI.BO trades at ₹132.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LENSKART.BO currently has a P/E ratio of 243.62, whereas KMSMEDI.BO's P/E ratio is 179.46. In terms of profitability, LENSKART.BO's ROE is +0.09%, compared to KMSMEDI.BO's ROE of +0.03%. Regarding short-term risk, LENSKART.BO is more volatile compared to KMSMEDI.BO. This indicates higher risk in terms of short-term price fluctuations for LENSKART.BO.Check KMSMEDI.BO's competition here
GKB Ophthalmics Limited (BSE: GKB.BO)
LENSKART.BO vs GKB.BO Comparison September 2026
Lenskart Solutions Limited (BSE: LENSKART.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LENSKART.BO stands at 1.2T. In comparison, GKB.BO has a market cap of 315M. Regarding current trading prices, LENSKART.BO is priced at ₹706.60 on the BSE, while GKB.BO trades at ₹62.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LENSKART.BO currently has a P/E ratio of 243.62, whereas GKB.BO's P/E ratio is -10.19. In terms of profitability, LENSKART.BO's ROE is +0.09%, compared to GKB.BO's ROE of +0.06%. Regarding short-term risk, LENSKART.BO is more volatile compared to GKB.BO. This indicates higher risk in terms of short-term price fluctuations for LENSKART.BO.Check GKB.BO's competition here
Kretto Syscon Limited (BSE: KRETTOSYS.BO)
LENSKART.BO vs KRETTOSYS.BO Comparison September 2026
Lenskart Solutions Limited (BSE: LENSKART.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LENSKART.BO stands at 1.2T. In comparison, KRETTOSYS.BO has a market cap of 270.9M. Regarding current trading prices, LENSKART.BO is priced at ₹706.60 on the BSE, while KRETTOSYS.BO trades at ₹0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LENSKART.BO currently has a P/E ratio of 243.62, whereas KRETTOSYS.BO's P/E ratio is 222.22. In terms of profitability, LENSKART.BO's ROE is +0.09%, compared to KRETTOSYS.BO's ROE of +0.00%. Regarding short-term risk, LENSKART.BO is more volatile compared to KRETTOSYS.BO. This indicates higher risk in terms of short-term price fluctuations for LENSKART.BO.Check KRETTOSYS.BO's competition here
Novateor Research Laboratories (BSE: NOVATEOR.BO)
LENSKART.BO vs NOVATEOR.BO Comparison September 2026
Lenskart Solutions Limited (BSE: LENSKART.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LENSKART.BO stands at 1.2T. In comparison, NOVATEOR.BO has a market cap of 212.4M. Regarding current trading prices, LENSKART.BO is priced at ₹706.60 on the BSE, while NOVATEOR.BO trades at ₹35.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LENSKART.BO currently has a P/E ratio of 243.62, whereas NOVATEOR.BO's P/E ratio is 206.47. In terms of profitability, LENSKART.BO's ROE is +0.09%, compared to NOVATEOR.BO's ROE of N/A. Regarding short-term risk, LENSKART.BO is more volatile compared to NOVATEOR.BO. This indicates higher risk in terms of short-term price fluctuations for LENSKART.BO.Check NOVATEOR.BO's competition here
Span Divergent Limited (BSE: SDL.BO)
LENSKART.BO vs SDL.BO Comparison September 2026
Lenskart Solutions Limited (BSE: LENSKART.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LENSKART.BO stands at 1.2T. In comparison, SDL.BO has a market cap of 201.3M. Regarding current trading prices, LENSKART.BO is priced at ₹706.60 on the BSE, while SDL.BO trades at ₹27.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LENSKART.BO currently has a P/E ratio of 243.62, whereas SDL.BO's P/E ratio is 125.43. In terms of profitability, LENSKART.BO's ROE is +0.09%, compared to SDL.BO's ROE of +2.01%. Regarding short-term risk, LENSKART.BO is more volatile compared to SDL.BO. This indicates higher risk in terms of short-term price fluctuations for LENSKART.BO.Check SDL.BO's competition here